Abstract |
Pixantrone ( BBR2778) is a novel anthracycline derivative, manufactured by Cell Therapeutics Incorporated, WA, USA. In both preclinical and clinical studies pixantrone exhibited a significantly lower cardiac toxicity and better activity than that observed with alternative anthracyclines, as it is devoid of the putative cardiac toxicity generating 5,8-dihydroxy groups. With single-agent pixantrone, neutropenia was the dose-limiting toxicity. In relapsed aggressive non-Hodgkin lymphomas, weekly single-agent pixantrone 85 mg/m(2) for 3 weeks every 4 weeks was associated with a 27% overall response rate and a 15% complete response rate. When used in combination with chemotherapy regimens overall response rates of 58-74% and complete response rates of 37-57% were achieved.
|
Authors | Loaie M El-Helw, Barry W Hancock |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 5
Issue 4
Pg. 445-53
(May 2009)
ISSN: 1744-8301 [Electronic] England |
PMID | 19450173
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Isoquinolines
- pixantrone
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Clinical Trials as Topic
- Humans
- Isoquinolines
(pharmacology)
- Lymphoma, Non-Hodgkin
(drug therapy)
|